In the biotech market, Thermo Fisher Scientific Inc. (TMO) is gaining attention for numerous aspects. Being identified as an innovative healthcare stock to watch till 2025 and considering its financial outlook, TMO was considered a worthy investment by most analysts, despite some estimating an earnings decline. There are notable points of attraction towards the stock like their provisions for an advanced therapies collaboration center in San Diego, launching of the 5L DynaDrive Single-Use Bioreactor, and a partnership with the Chan Zuckerberg Institute for Advanced Biological Imaging. TMO also acquired Solventum’s Purification and Filtration Business and launched several innovative products such as the Krios 5 Cryo-Transmission Electron Microscope (TEM) and a sustainable centrifuge line. Stocks were reportedly dumped in March but bounced back with a 1.3% increase and reports of strong Q4 results and robust 2025 profit projections. Several future positive prospects, like a $4.1B Biologics Filtration Acquisition and renewable energy agreements, suggest continued growth.
Thermo Fisher Scientific TMO News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Fri, 18 Apr 2025 14:04:05 GMT - Rating 7 - Innovation 8 - Information 9 - Rumor 2
